Peters James (Orcid ID: 0000-0001-7533-4388)
Vijaratnam Nirosen (Orcid ID: 0000-0002-9671-0212)

1
Anti-Ma2 associated paraneoplastic encephalitis
Eat, Sleep and Repeat

Author details: James Peters, MBBS; Nirosen Vijaratnam, MBBS, BMedSci, FRACP; Kar Yan Lo, MBBS, FRACP; Andrew H. Evans, MBBS, FRACP, MD

James Peters, Department of Neurology, Western Health
Nirosen Vijaratnam, Department of Neurology, The Royal Free Hospital
Kar Yan Lo, Department of Neurology, Western Health
Andrew H. Evans, Movement Disorder Service, Department of Neurology, The Royal Melbourne Hospital

Corresponding Author
Dr. James Peters
Department of Neurology, Western Health
176 Furlong Road, St Albans, VIC 3021
jamespeters637@gmail.com
+61 404 842 262

Acknowledgements: Nil

Word count
Abstract: 59
Main text: 496

Key words: paraneoplastic encephalitis, anti-Ma2 associated encephalitis, anti-Ma2 antibodies, narcolepsy, REM sleep behaviour disorder

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/imj.14349](https://doi.org/10.1111/imj.14349)

Anti-Ma2 associated paraneoplastic encephalitis

Eat, Sleep and Repeat

Abstract:

Anti-Ma2 associated paraneoplastic encephalitis (PNE) is a syndrome characterised by dysfunction of the diencephalon, brainstem and limbic systems. We describe a rare presentation with narcolepsy type 1 and a REM sleep behaviour disorder to promote familiarity amongst general and respiratory physicians who will potentially be the first to encounter these patients. An early diagnosis potentially ensures a favourable prognosis.

More familiar presentations of paraneoplastic encephalitis (PNE) include seizures, depression and cognitive decline. A rare cause described is antibodies against the onconeural protein Ma2¹. Increasing experience suggests that it differs from other forms of PNE². We describe a case that highlights this contrasting presentation.

A 35-year-old male suffered from excessive day time sleepiness (EDS) which worsened over 6-months, requiring up to 16-hours of sleep daily. Sleep periods were characterised by dream-enacting behaviour. He further experienced sugar cravings, waking only to seek carbohydrates. Brainstem dysfunction developed with diplopia progressing to vertical ophthalmoparesis. Frontal cognitive impairment, the only classical PNE feature to emerge, became apparent 2-years after the initial presentation.

Sleep review resulted in a diagnosis of narcolepsy type 1 (NT1) with a rapid eye movement (REM) sleep behaviour disorder (RBD). Polysomnography and Multiple Sleep Latency Testing showed a mean sleep latency of 2.8 minutes and multiple periods of REM sleep occurring 15 minutes from sleep onset. HLA genotyping was not performed. The narcolepsy was unresponsive to both non-amphetamine and amphetamine agents.

Other investigations were only pursued when further progression occurred. MRI brain showed FLAIR hyperintensities in the right medial temporal lobe and CSF analysis demonstrated a protein of 0.54g/L and 4 lymphocytes. The EEG suggested encephalopathy. Basic bloods and initial cerebral Tc-99m-hexamethylpropylene amine oxime imaging were unremarkable. Anti-Ma2 antibodies were isolated in the CSF and serum at a titre of 1:10 and 1:160 respectively while other paraneoplastic antibodies were undetected. Malignancy screening with CT, FDG-PET scan and testicular ultrasound were negative. Bilateral orchidectomy was pursued given a known association¹ and histopathology demonstrated diffuse intratubular germ cell neoplasia.

Steroids, immunoglobulins, cyclophosphamide and rituximab were used in combination following tumour resection. Mild neurological improvement was initially observed but stagnated. No single immunotherapy appeared more effective. Repeat cerebral SPECT imaging showed increasing right temporal perfusion correlating with increasing flair hyperintensity in the right temporal region. The development of refractory temporal pole seizures contributed to further neurological disability and ultimately death.

To our knowledge this is the third documented case of anti-Ma2 associated encephalitis presenting with NT1 and a RBD²⁻⁴. However EDS has been noted in up to 32% of cases². Idiopathic NT1 is caused by selective loss of the hypothalamic hypocretin-synthesizing neurons³. Hypocretin promotes wakefulness and inhibits REM sleep. Low or undetectable levels in these subjects suggest a similar pathogenesis²⁻⁴. 98% of subjects with idiopathic NT1 carry the HLA-DQB1*0602 allele⁵. Tested in one of the three cases, the absence of the allele emphasises the importance of HLA genotyping³.

While death was the outcome in this case, analysis of 38 cases have demonstrated neurological improvement or stabilization in 50% of patients following treatment². Limited CNS involvement at diagnosis and a tumour responsive to therapy were favourable prognostic features². This case illustrates the initial presentation of anti-Ma2 associated encephalitis with NT1 and RBD. It highlights the importance of a heightened clinical suspicion amongst sleep physicians to ensure an early diagnosis. In retrospect, HLA genotyping as a part of the sleep review, may have prompted a timelier diagnosis.

1. Voltz R, Gultekin H, Rosenfeld MR, Gerstner E, Eichen J, Posner J, et al. A Serologic Marker of Paraneoplastic Limbic and Brain-Stem Encephalitis in Patients with Testicular Cancer. *N Engl J Med* 1999; **340**: 1788-1795.

2. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. *Brain* 2004; **127**: 1831–1844
3. Compta Y, Iranzo A, Santamaría J, Casamitjana R, Graus F. REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis. *Sleep* 2007; **30**: 767–769.
4. Dauvilliers Y, Bauer J, Rigau V, Lalloyer N, Labauge P, Carlander B, et al. Hypothalamic Immunopathology in Anti-Ma–Associated Diencephalitis With Narcolepsy-Cataplexy. *JAMA Neurology* 2013; **70**: 1305-1310.
5. Tafti M, Hor H, Dauvilliers Y, Lammers G, Overeem S, Mayer G, et al. DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe. *Sleep* 2014; **37**: 19–25.

Anti-Ma2 associated paraneoplastic encephalitis

Eat, Sleep and Repeat

Author details: James Peters, MBBS; Nirosen Vijaratnam, MBBS, BMedSci, FRACP; Kar Yan Lo, MBBS, FRACP; Andrew H. Evans, MBBS, FRACP, MD

James Peters, Department of Neurology, Western Health

Nirosen Vijaratnam, Department of Neurology, The Royal Free Hospital

Kar Yan Lo, Department of Neurology, Western Health

Andrew H. Evans, Movement Disorder Service, Department of Neurology, The Royal Melbourne Hospital

Corresponding Author

Dr. James Peters

Department of Neurology, Western Health

176 Furlong Road, St Albans, VIC 3021

jamespeters637@gmail.com

+61 404 842 262

Acknowledgements: Nil

Word count

Abstract: 59

Main text: 496

Key words: paraneoplastic encephalitis, anti-Ma2 associated encephalitis, anti-Ma2 antibodies, narcolepsy, REM sleep behaviour disorder

Anti-Ma2 associated paraneoplastic encephalitis

Eat, Sleep and Repeat

Abstract:

Anti-Ma2 associated paraneoplastic encephalitis (PNE) is a syndrome characterised by dysfunction of the diencephalon, brainstem and limbic systems. We describe a rare presentation with narcolepsy type 1 and a REM sleep behaviour disorder to promote familiarity amongst general and respiratory physicians who will potentially be the first to encounter these patients. An early diagnosis potentially ensures a favourable prognosis.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Peters, J;Vijiaratnam, N;Lo, KY;Evans, AH

Title:

Anti-Ma2-associated paraneoplastic encephalitis eat, sleep and repeat

Date:

2019-07-01

Citation:

Peters, J., Vijiaratnam, N., Lo, K. Y. & Evans, A. H. (2019). Anti-Ma2-associated paraneoplastic encephalitis eat, sleep and repeat. INTERNAL MEDICINE JOURNAL, 49 (7), pp.931-932. <https://doi.org/10.1111/imj.14349>.

Persistent Link:

<http://hdl.handle.net/11343/286066>